Navigation Links
Peregrine Pharmaceuticals Forms Anti-Viral Research Group to Oversee Its Anti-PS Infectious Disease Collaborations
Date:10/7/2009

.

Bavituximab is also being tested in Phase II clinical trials for the treatment of advanced breast cancer and non-small cell lung cancer.

Peregrine's work on viral hemorrhagic fevers is funded by the Transformational Medical Technologies Initiative (TMTI) under contract HDTRA1-08-C-0003.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and serious virus infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(®). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the Company will not receive the full $44.4 million awarded under the TMTI program. the risk that bavituximab will not achieve broad-spectrum anti-viral effects and the risk that PS-targeting antibodies will not be less susceptible to viral mutations. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara(R) for Treatment of Brain Cancer
2. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
3. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
4. Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
5. Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrines Fully Human Anti-PS Antibody in Prostate Cancer Model
6. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
7. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
8. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
9. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
10. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)...  Express Scripts (NASDAQ: ESRX ) today ... Medicare ® Prescription Drug Plans (PDP) will offer ... WAG ) (NASDAQ: WAG ), helping ...  for their Medicare dollars. Medicare beneficiaries who ... or Choice plans for 2015 can save ...
(Date:10/1/2014)... , Oct. 1, 2014   Royal ... PHIA) today announced its eCareCoordinator and eCareCompanion telehealth ... Food and Drug Administration (FDA). A part of ... programs , eCareCoordinator and eCareCompanion are focused on ... first clinical applications to be available through the ...
(Date:10/1/2014)... 2014 Ardelyx, Inc. (NASDAQ: ... focused on cardio-renal, gastrointestinal and metabolic diseases, ... patient Phase 2b clinical trial evaluating tenapanor ... (IBS-C).  Results from this study demonstrated statistically ... symptoms for tenapanor-treated patients compared to patients ...
Breaking Medicine Technology:Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 2Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 3Express Scripts Collaborates with Walgreens to Create Value-Driven Medicare Prescription Drug Plan Pharmacy Network 4Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 2Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 3Philips Secures 510(k) Clearance to Market the First Clinical Applications for its new Digital Health Platform 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6
... Colo., Dec. 19, 2011   LABS, Inc., a global, ... expertise in regulated testing for human organs, cells, tissues ... named Company of the Year by the 2011 Colorado ... and honors individuals and companies that have made a ...
... Accuray Incorporated (Nasdaq: ARAY ), the ... medical centers globally have installed both a CyberKnife ... System enabling the delivery of personalized treatment for the ... smaller community sites in rural areas, mid-sized regional hospitals ...
Cached Medicine Technology:LABS, Inc. Named Colorado's Bioscience Company of the Year 2LABS, Inc. Named Colorado's Bioscience Company of the Year 3Medical Centers Worldwide Adopt Both Accuray's CyberKnife and TomoTherapy Systems 2Medical Centers Worldwide Adopt Both Accuray's CyberKnife and TomoTherapy Systems 3Medical Centers Worldwide Adopt Both Accuray's CyberKnife and TomoTherapy Systems 4
(Date:10/1/2014)... Journal of the American Medical Association shows ... or severe chronic knee pain, acupuncture did not provide ... randomly assigned 282 patients (50 years or older) with ... pretend laser treatment. , Treatments were delivered for ... and sham (inactive) laser acupuncture. , Researcher Professor Kim ...
(Date:10/1/2014)... New research suggests the adage that encourages people to ... target when it comes to exercise. When walking, staying ... distance to it appear shorter and help people walk ... compares this technique to walking while looking around the ... quality of exercise. , "People are less interested in ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog post explaining how ... , Smoking will always have a negative impact on ... method to find affordable coverage. Insurance brokerage websites specialize ... , Whole life insurance premiums will be fixed throughout ... is permanent, the initial rates are very important. ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Join the more ... Eating Disorder Treatment Center’s first ever charity golf tournament to ... people with eating disorders who cannot afford treatment. The tournament ... Club in Eureka, Mo. , The day-long event starts ... A reception and award dinner will begin at 5 p.m. ...
(Date:10/1/2014)... 01, 2014 Diet Doc understands that many ... lose weight and their dieting attempts could be easily sabotaged ... hormone diet treatments into their programs as a ... see fast and effective weight loss results, it also allows ... habits to maintain their weight for the future. , Earlier ...
Breaking Medicine News(10 mins):Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 2Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 3Health News:Diet Doc Announces Their New Version of the Hormone Diet Plan to Target, Attack and Burn Fat Without Dangerous Side Effects 4
... United Kingdom and hires Michael Dyson to run European operations. ... ... DNA2.0, the leading gene synthesis and protein engineering company, today announced ... the United Kingdom-based DNA2.0 Ltd. Michael Dyson, PhD, has been appointed ...
... May help avoid incorrect Breast Cancer diagnosis and management ... 10 /PRNewswire-FirstCall/ - Predictive medicine company PreMD Inc. (TSX: ... provisional patent application that describes a new simplified method ... application was filed with the United States Patent and ...
... 10 Prime Therapeutics LLC (Prime),announces that it has ... Montana,(BCBSMT) to provide commercial pharmacy benefit management services, beginning,January ... Prime will provide pharmacy benefit services to more than ... drug coverage. The,three-year contract covers a range of pharmacy ...
... these medications may be reason, study suggests , , TUESDAY, ... prescription drugs, primarily pain relievers, appear to be ... suggests. , West Virginia, in particular, has seen a ... who have uncovered patterns of "doctor shopping" for drugs ...
... Award-Winning Recording Artist Toni Braxton and Her Son Featured in ... NEW YORK, Dec. 10 The Advertising Council, in ... new series of public service advertisements (PSAs) featuring Grammy award-winning ... raise awareness about autism and to urge parents to learn ...
... be faced with a national health care crisis in the ... a growing number of older adults find themselves diagnosed with ... of a team of researchers from across the country who ... older patients at risk of or dealing with cancer are ...
Cached Medicine News:Health News:DNA2.0 Expands European Presence By Opening UK Office: Experienced Life Sciences Executive, Dr. Michael Dyson, to Lead European Operations 2Health News:PreMD Files Provisional Patent Application Describing a New Method of Quantifying Cancer Biomarkers 2Health News:PreMD Files Provisional Patent Application Describing a New Method of Quantifying Cancer Biomarkers 3Health News:Prime Therapeutics Announces Blue Cross and Blue Shield of Montana as a Pharmacy Benefit Services Client 2Health News:Painkillers Linked to Increase in Overdose Deaths 2Health News:Painkillers Linked to Increase in Overdose Deaths 3Health News:Video: The Advertising Council and Autism Speaks Launch New PSAs to Raise Awareness of Autism 2Health News:Video: The Advertising Council and Autism Speaks Launch New PSAs to Raise Awareness of Autism 3Health News:Video: The Advertising Council and Autism Speaks Launch New PSAs to Raise Awareness of Autism 4Health News:Surge in older cancer survivors expected as baby boomers age 2Health News:Surge in older cancer survivors expected as baby boomers age 3
Improve your refractive outcome, with AXIS II precision biometry A-scan. Biometry clinically proven as accurate as partial coherence interferometry while not limited by dense media....
... with graphic display and IOL power ... combination units include firmware module with ... II formulas. Audible tones increase in ... visual axis. Constant tone when alignment ...
... ISYSTEM-ABD ("I-cubed") is an exceptionally high ... analog oscilloscope (static deflection) display. This ... than low cost video monitors. Vitreous ... inflammatory cells, as well as tumor ...
... a sensitive B-scan system which quickly identifies ocular ... both eyes differ by more than 0.3 mm, ... suspected. The B5500 enables quick and easy identification ... bath or inserting shells under the lids. The ...
Medicine Products: